Xencor, Inc. (XNCR)
US — Healthcare Sector
Automate Your Wheel Strategy on XNCR
With Tiblio's Option Bot, you can configure your own wheel strategy including XNCR - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol XNCR
- Rev/Share 1.7704
- Book/Share 8.686
- PB 0.921
- Debt/Equity 0.106
- CurrentRatio 5.8943
- ROIC -0.2006
- MktCap 569366400.0
- FreeCF/Share -2.349
- PFCF -3.2903
- PE -2.7668
- Debt/Assets 0.075
- DivYield 0
- ROE -0.327
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 4
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | XNCR | William Blair | -- | Outperform | -- | -- | April 21, 2025 |
| Initiation | XNCR | Wells Fargo | -- | Overweight | -- | $37 | Dec. 12, 2024 |
News
Xencor (XNCR) Reports Q1 Loss, Tops Revenue Estimates
XNCR
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Published: May 07, 2025 by: Zacks Investment Research
Sentiment: Negative
Xencor (XNCR) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.63. This compares to loss of $1.11 per share a year ago.
Read More
Xencor (XNCR) Upgraded to Buy: Here's Why
XNCR
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Xencor (XNCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Read More
About Xencor, Inc. (XNCR)
- IPO Date 2013-12-03
- Website https://www.xencor.com
- Industry Biotechnology
- CEO Dr. Bassil I. Dahiyat Ph.D.
- Employees 250
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression. It has a license agreement with Caris Life Sciences. Xencor, Inc. was incorporated in 1997 and is headquartered in Monrovia, California.